Clinical trials: Drug Induced Parkinson's Disease
Parkinson's Disease, Parkinsonian Syndrome
Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
The purpose of the study is to determine the sensitivity and specificity of transcranial duplex scanning (TCD) and single photon emission computer tomography (SPECT) in patients suspected of having Idiopathic Parkinson Disease…
- Conditions
- Parkinson's Disease, Parkinsonian Syndrome, Multiple System Atrophy, Supranuclear Palsy, Progressive
- Trial name
- NCT00368199
- Where
- Netherlands
- Volunteers
- 196 people
- Sponsor
- Maastricht University Medical Center
Parkinson Disease, Impulse Control Disorder
Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease
Impulse control disorders and related behaviors (ICDRBs) are characterized by pathological gambling, compulsive shopping or eating, and hypersexuality, but other related behaviors have been described, e.g. hobbyism, and punding.
- Trial name
- PREVENT-ICD (NCT07505394)
- Testing
- Algorithm-guided group, Standard of Care (SoC) group
- Where
- France
- Volunteers
- 528 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Secondary Parkinsonism, Parkinson's Disease
Degenerative Nigrostriatal Dysfunction in Drug-induced Parkinsonism
Parkinson's disease (PD) and Drug-induced Parkinsonism (DIP) can be clinically indistinguishable and DIP sometimes represents "unmasking of underlying PD.
- Trial name
- NCT02361255
- Testing
- no intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Parkinson Disease, Idiopathic
An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease
This clinical study is designed to explore the safety and tolerability of UX-DA001. It will also explore if UX-DA001 works to improve motor function in subjects with Parkinson's disease.
- Trial name
- NCT06778265
- Testing
- UX-DA001
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai UniXell Biotechnology Co., Ltd
Parkinson Disease, Dyskinesia, Drug-Induced
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day).
- Conditions
- Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
- Trial name
- NCT04857359
- Testing
- Dipraglurant
- Where
- 41 sites in United States
- Volunteers
- 25 people
- Sponsor
- Addex Pharma S.A.
Medication-Induced Dyskinesia
Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA…
- Trial name
- NCT05148884
- Testing
- NLX-112
- Where
- 5 sites in Sweden
- Volunteers
- 27 people
- Sponsor
- Neurolixis SAS
Idiopathic Parkinson's Disease, Drug Induced Dyskinesia
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of Parkinson's disease (PD)…
- Trial name
- TOP-DYSK (NCT01789047)
- Testing
- Topiramate, Amantadine
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Rush University Medical Center
Dyskinesia, Medication-induced, Dyskinesia, Drug-Induced
Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia
The goal of this clinical trial is to test Safety and tolerability of single and repeated dose of IMM02-KORA in subjects with PD-associated dyskinesia.
- Trial name
- KORA-LID-1 (NCT07905976)
- Testing
- IMM02-KORA
- Volunteers
- 15 people
- Sponsor
- Immunis, Inc.
Parkinson's Disease, Alzheimer's Disease
Biomarkers in Neural Disorders
This study seeks to establish the sensitivity and specificity of what appears to be a unique brainstem biomarker of Parkinson's Disease (PD) - an electrically induced olygosynaptic nasotrigeminal reflex response - in…
- Conditions
- Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor
- Trial name
- NCT02761707
- Testing
- Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Parkinson Disease, Dyskinesia, Drug-Induced
Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
In this study, the investigators will examine the association of statin use and dyskinesia in a convenience sample Parkinson's disease patients in the Veterans Administration Health Care System.
- Trial name
- STAT-PD (NCT04064294)
- Testing
- Intravenous Infusion
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- VA Office of Research and Development
Parkinson's Disease, Dyskinesia
Capturing Parkinson's Disease Medication Side Effects During Daily Activities
The purpose of the study is to test whether body-worn wireless motion sensors can measure dyskinesias (involuntary movements caused by medications) in individuals with Parkinson disease (PD) independent of voluntary activity…
- Trial name
- NCT01429207
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Movement Disorders, Essential Tremor
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
The proposed study is to evaluate the effectiveness of ExAblate Transcranial MRgFUS as a tool for creating a unilateral lesion in the Vim thalamus or the globus pallidus (GPi) in patients with treatment-refractory symptoms of…
- Conditions
- Movement Disorders, Essential Tremor, Holmes Tremor, Parkinson's Disease
- Trial name
- NCT02252380
- Testing
- Transcranial ExAblate System
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- InSightec
Parkinson's Disease
Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia
This Phase IIb exploratory study is designed to determine whether AFQ056 is safe and effective and whether it can increase the therapeutic window of L-dopa in patients whose control of their Parkinson's Disease symptoms is…
- Trial name
- NCT01092065
- Testing
- AFQ056 with L-dopa
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Novartis
Parkinson Disease, Dyskinesia, Medication-Induced
AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia
This is a randomized, double-blind, placebo-controlled, crossover, proof-of-concept Phase 2 study to test efficacy and safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease subjects with levodopa-induced dyskinesia.
- Conditions
- Parkinson Disease, Dyskinesia, Medication-Induced, L-Dopa Causing Adverse Effects in Therapeutic Use
- Trial name
- NCT04147949
- Testing
- AV-101
- Volunteers
- 20 people
- Sponsor
- VistaGen Therapeutics, Inc.
Parkinson's Disease, Drug-induced Parkinsonism
Effect of Exercise in Parkinsonism
Parkinson's disease (PD) is a common neurodegenerative disorder affecting approximately 80,000 Veterans, representing a priority area for VA research.
- Trial name
- NCT02598973
- Testing
- Exercise
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Dyskinesia, Medication-Induced, Parkinson's Disease
Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)
This is a randomized sham-controlled double-blind study to test the hypothesis that transcranial static magnetic field stimulation (tSMS) of the motor cortex improves levodopa-induced dyskinesias in patients with Parkinson's…
- Trial name
- NCT02657681
- Testing
- tSMS
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Fundación de investigación HM
Dyskinesias, Drug-induced
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.
- Trial name
- NCT01474421
- Testing
- AQW051
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Dyskinesia, Drug-Induced, Parkinson Disease
Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease
Using a within-subject cross-over design, we will include 20 patients with Parkinson disease (PD) and peak-of-dose dyskinesia. Patients will be studied after withdrawal from their normal dopaminergic medication.
- Trial name
- NCT03354455
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Danish Research Centre for Magnetic Resonance
Schizophrenia, Major Depressive Disorder
Clinical Registry of Patients Under Treatment With Atypical Antipsychotics
Antipsychotic drugs are characterized by blocking dopaminergic D2 receptors. They have been found to be effective and safe for the treatment of schizophrenia, bipolar disorders, depressive episodes associated with bipolar…
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar Depressive Disorder, Parkinson's Disease With Hallucinations
- Trial name
- NCT02409823
- Testing
- Atypical Antipsychotics
- Volunteers
- 665 people
- Sponsor
- Pontifical Catholic University of Argentina
PARKINSON DISEASE (Disorder), Cell Therapy
A Phase 1 Study of NCR201 in Parkinson's Disease Patients With Prior DBS
This is a Phase 1 clinical trial to evaluate the safety and tolerability of a new cell therapy called NCR201. The study will enroll adults with moderate-to-advanced primary Parkinson's disease who have previously undergone deep…
- Conditions
- PARKINSON DISEASE (Disorder), Cell Therapy, Human Induced Pluripotent Stem Cells, Deep Brain Stimulation
- Trial name
- NCR201-2004 (NCT07896187)
- Testing
- NCR201
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.